We develop innovative drugs for the treatment of rare respiratory diseases.
Savara focuses on developing new inhalation treatments for patients who suffer from rare and serious respiratory diseases. We are advancing a pipeline based on three compounds that have been widely used before as active pharmaceutical ingredients in medicinal products licensed for systemic use but, never in medicinal products licensed for inhalation. By delivering these compounds directly to the lungs of the patients, the clinical efficacy is expected to improve and the adverse effects are expected to be reduced compared to systemic use.
The compounds are:
- Sodium Nitrite
We reposition these compounds considering:
- New unique formulations
- New administration routes
- New indications
We develop the compounds for the treatment of patients suffering from:
- Pulmonary alveolar proteinosis (PAP)
- Cystic fibrosis (CF)
- Nontuberculous mycobacteria (NTM) lung infection
- Heart failure with preserved ejection fraction (HFpEF)
These conditions are serious and have a high medical priority due to the lack of effective treatments or due to the invasiveness or risks associated with currently available therapies.